{
  "id": "602820fb1cb411341a0000f7",
  "type": "list",
  "question": "Which drugs are included in the CAPOX chemotherapy regimen for colorectal cancer?",
  "ideal_answer": "CAPOX chemotherapy regimen for colorectal cancer includes capecitabine plus oxaliplatin.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33023657",
    "http://www.ncbi.nlm.nih.gov/pubmed/19949897",
    "http://www.ncbi.nlm.nih.gov/pubmed/20643620",
    "http://www.ncbi.nlm.nih.gov/pubmed/31254462",
    "http://www.ncbi.nlm.nih.gov/pubmed/33790157",
    "http://www.ncbi.nlm.nih.gov/pubmed/17079693",
    "http://www.ncbi.nlm.nih.gov/pubmed/32399998",
    "http://www.ncbi.nlm.nih.gov/pubmed/28174487",
    "http://www.ncbi.nlm.nih.gov/pubmed/33144447",
    "http://www.ncbi.nlm.nih.gov/pubmed/27330345",
    "http://www.ncbi.nlm.nih.gov/pubmed/31832229",
    "http://www.ncbi.nlm.nih.gov/pubmed/32588749",
    "http://www.ncbi.nlm.nih.gov/pubmed/32053133",
    "http://www.ncbi.nlm.nih.gov/pubmed/21063416",
    "http://www.ncbi.nlm.nih.gov/pubmed/30248163",
    "http://www.ncbi.nlm.nih.gov/pubmed/33977607",
    "http://www.ncbi.nlm.nih.gov/pubmed/32994804",
    "http://www.ncbi.nlm.nih.gov/pubmed/17653254",
    "http://www.ncbi.nlm.nih.gov/pubmed/29802221",
    "http://www.ncbi.nlm.nih.gov/pubmed/32156916",
    "http://www.ncbi.nlm.nih.gov/pubmed/18544957",
    "http://www.ncbi.nlm.nih.gov/pubmed/17548840",
    "http://www.ncbi.nlm.nih.gov/pubmed/33215454",
    "http://www.ncbi.nlm.nih.gov/pubmed/21300933",
    "http://www.ncbi.nlm.nih.gov/pubmed/34877325",
    "http://www.ncbi.nlm.nih.gov/pubmed/18361802",
    "http://www.ncbi.nlm.nih.gov/pubmed/29423680",
    "http://www.ncbi.nlm.nih.gov/pubmed/33340853"
  ],
  "snippets": [
    {
      "text": "Objective: To assess the noninferiority and toxic effects of 3 vs 6 months of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin) adjunct chemotherapy among patients with high-risk stage II resected colorectal cancer enrolled in the TOSCA trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32053133",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32399998",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "WHAT IS KNOWN AND OBJECTIVE: High interindividual response variability was reported with capecitabine and oxaliplatin (CAPOX) regimen in colorectal cancer (CRC). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32399998",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, adjuvant colorectal cancer treatment primarily includes chemotherapeutic regimens such as FOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin) or CAPOX (capecitabine, oxaliplatin), as well as alternative regimens such as TOMOX (raltitrexed, oxaliplatin). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32588749",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The proportion of patients showing CR was low in the carboplatin (CBDCA)- and oxaliplatin-based chemotherapy groups, especially among women. We showed that the CR rates in men were high in the CBDCA (AUC5)\u2009+\u2009etoposide (ETP) (80%), capecitabine plus oxaliplatin (CAPOX) (78%), and CBDCA+ paclitaxel (PTX) groups for lung cancer (73%). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33023657",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Methods: Using the validated PATTERN Markov cohort model, which simulates the disease progression of stage II CC patients from diagnosis to death, we first evaluated a reference strategy in which high-risk patients were treated with chemotherapy for 6\u2009months. In the second strategy, treatment duration was shortened to 3\u2009months. Both strategies were evaluated for CAPOX (capecitabine plus oxaliplatin) and FOLFOX (fluorouracil, leucovorin and oxaliplatin). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32994804",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The oral fluoropyrimidine capecitabine has been effectively and safely combined with irinotecan (CAPIRI) and/or oxaliplatin (CAPOX).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18361802",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31254462",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ents receiving the chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) after radical resection of colorectal cancer were prospectively collected and randomly divided into an experimental group and a control group. The",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34877325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "LTS: The completion rate of each chemotherapy regimen was 10 out of 16 patients in oral uracil-tegafur plus leucovorin (UFT/LV), 1 out of 3 patients in oral capecitabine (Capecitabine) and 2 out of 14 patients in capecitabine plus oxaliplatin (CAPOX). The",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33144447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Capecitabine plus oxaliplatin (CAPOX) is an established treatment option in colorectal cancer, but can be associated with severe t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21063416",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "rent standard treatment for recurrent or metastatic colon cancer uses capecitabine plus oxaliplatin (CAPOX), or continuous-infusion fluorouracil plus oxaliplatin (FOLFOX). This ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19949897",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "LESSONS LEARNED: Three-month adjuvant capecitabine plus oxaliplatin in combination (CAPOX) appeared to reduce recurrence, with mild toxicity in postcurative resection of colorectal cancer liver me",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33977607",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "WHAT IS KNOWN AND OBJECTIVE: High interindividual response variability was reported with capecitabine and oxaliplatin (CAPOX) regimen",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32399998",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "of life. This study evaluated the efficacy and safety of capecitabine plus oxaliplatin (CAPOX) with intermittent oxaliplatin use compared with the standard CAPOX in adjuvant therapy for colon",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33340853",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " combinations are available in NZ in the metastatic setting, with the most popular being oxaliplatin/capecitabine combination (CAPOX) (35%) or irinotecan/5-FU combination (FOLFIRI) (23%). None of the respondents w",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653254",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "urrently, adjuvant colorectal cancer treatment primarily includes chemotherapeutic regimens such as FOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin) or CAPOX (capecitabine, oxaliplatin), as well as alternative regimens such as TOMOX (raltitrexed, oxaliplatin). However,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32588749",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e capecitabine has been effectively and safely combined with irinotecan (CAPIRI) and/or oxaliplatin (CAPOX). Three randomized phase I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18361802",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background: Capecitabine and oxaliplatin (CAPOX) chemotherapy is a standard treatment for stage 2/3 colore",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31832229",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[Capecitabine and Oxaliplatin(CAPOX)plus Bevacizumab as Second-Line Chemotherapy for Metastatic Colorectal Cancer].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33790157",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ional Chinese Medicine. Patients receiving the chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) after radical resection of colorectal cancer were prospectively collected and randomly divided into an experimental gr",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34877325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, adjuvant colorectal cancer treatment primarily includes chemotherapeutic regimens such as FOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin) or CAPOX (capecitabine, oxaliplatin), as well as alternative regimens such as TOMOX (raltitrexed, oxaliplatin).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32588749",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Systemic chemotherapy was administered comprising a capecitabine/oxaliplatin(CAPOX)regimen.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32156916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "y cycle.METHODS: Thirty-eight colorectal cancer patients scheduled to receive the leucovorin, 5'-fluorouracil, oxaliplatin (FOLFOX) therapy or the capecitabine, oxaliplatin (CAPOX) thera",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29423680",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several chemotherapy combinations are available in NZ in the metastatic setting, with the most popular being oxaliplatin/capecitabine combination (CAPOX) (35%) or irinotecan/5-FU combination (FOLFIRI) (23%).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653254",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oxaliplatin-based chemotherapy (FOLFOX [folinic acid, fluorouracil, oxaliplatin] or XELOX [oxaliplatin, capecitabine; also called CAPOX]) for 6 months is the current standard for adjuvant therapy of stage III colon cancer patients with good performance status.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30248163",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "al cancers.MATERIALS AND METHODS: Eligibility criteria included diagnosis of colorectal cancers; eligible patients who were scheduled to undergo capecitabine monotherapy or capecitabine-oxaliplatin (CAPOX) fo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29802221",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Despite lack of a true comparative study, the folfox (5-fluorouracil-leucovorin-oxaliplatin) and capox (capecitabine-oxaliplatin) regimens are believed to be similar in their efficacy and tolerability in the treatment of stage iii colorectal cancer",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27330345",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he CAPOX regimen consisted of capecitabine (1000 mg/m2, in 2 divided doses for 14 d) and oxaliplatin (130 mg/m2 given on Day 1), repeated every 21 d for 8 cycles. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33215454",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18544957",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17079693",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "LESSONS LEARNED: Three-month adjuvant capecitabine plus oxaliplatin in combination (CAPOX) appeared to reduce recurrence, with mild toxicity in postcurative resection of colorectal cancer liver ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33977607",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: To evaluate the efficacy and tolerance of capecitabine (CAP) given every other week and biweekly oxaliplatin (OX; modified CAPOX regimen) in patients with advanced colorectal cancer previously treated with irinote- can-based frontline chemotherapy.METHODS: Sixty-seven patients were enrolled; the median age was 62 years and 62 (92.5%) had a performance ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18544957",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: To compare the use of capecitabine plus oxaliplatin (CAPOX) with infusional fluorouracil (FU)/folinic acid plus oxaliplatin (FUFOX) as first-line therapy for patients with metastatic colorectal cancer (MCRC).PATIENTS AND METHODS: A total of 474 patients with MCRC received either CAPOX (capecitabine 1,000 mg/m2 bid, days 1 to 14 plus oxaliplatin 70 mg/m2 days 1 and 8, repeated every 22 days) ) or FUFOX (oxaliplatin 50 mg/m2 followed by leucovorin 500 mg/m2 plus FU 2,000 mg/m2 as a 22-hour infusion days 1, 8, 15, a",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17548840",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: The aim of this prospective, single-arm phase II trial was to confirm the safety and efficacy of neoadjuvant chemotherapy (NAC) using oxaliplatin plus capecitabine (CapOX) for patients with operable locally advanced colon cancer (CC).METHODS: Patients with computed tomography-defined T4 or lymph node-positiv",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28174487",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Capecitabine has shown similar efficacy to 5-fluorouracil (5-FU); a regimen containing 2 weeks of capecitabine/oxaliplatin (CapOx) has demonstrated noninferiority to infusional 5-FU/oxaliplatin/leucovorin (FOLFOX) for the treatment of metastatic colorectal cance",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20643620",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine and irinotecan (CAPIRI) or capecitabine and oxaliplatin (CAPOX) in the first-line treatment of metastatic colorectal cancer (mCRC).PATIENTS AND METHODS: A total of 185 patients with mCRC were randomly assigned to cetuximab (400 mg/m(2) day 1, followed by 250 mg/m(2) weekly) plus CAPIRI (irinotecan 200 mg/m(2), day 1; capecitabine 800 mg/m(2) twice daily days 1 through 14, every 3 weeks; or cetuximab plus CAPOX (oxaliplatin 130 mg/m(2) day 1; capecitabine 1,000 mg/m(2) twice daily da",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300933",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Despite lack of a true comparative study, the folfox (5-fluorouracil-leucovorin-oxaliplatin) and capox (capecitabine-oxaliplatin) regimens are believed to be similar in their efficacy and tolerability in the treatment of stage iii colore",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27330345",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "capecitabine, oxaliplatin"
}